Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Chronic lung allograft dysfunction (CLAD) is the leading cause of long-term mortality after lung transplantation. Several risk factors for CLAD have been identified, but the exact pathophysiology and triggering molecular factors remain largely unknown. Moreover, in clinical practice, no integration of the different risk factors is achieved. CLAD is therefore diagnosed most often late with the persistent decline in respiratory function, revealing a profound and irreversible alteration of the pulmonary graft. Several blood biomarkers that can predict the occurrence of CLAD more than 6 months before clinical diagnosis have been identified and validated. From these preliminary results, a composite score is being developed from independent samples from the COLT (COhort in Lung Transplantation) cohort. The main objective of this project is to validate this robust and predictive composite score (biological and clinical) of CLAD.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lung transplant |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| MMP-9 levels in plasma, gene expression and lymphocyte levels in blood associated with Chronic Lung Allograft Dysfunction (CLAD) | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Expression of the 3 genes BLK, POU2AF1 and TCL1A in whole blood associated with CLAD | 3 years | |
| MMP-9 levels over time associated with CLAD | 3 years | |
| Transitional B lymphocytes rate over time associated with CLAD |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients newly enrolled on the waiting list in transplant centres will be included in the PRELUD study.
Based on the number of annual transplants in France (300/year), we plan to include 240 patients at the time of their registration on the transplant waiting list. Of these 240 patients, we estimate that 190 patients will be transplanted.
It will be possible to include patients in emergencies. In this case, the consent of a trusted person or relative will be obtained and then the patient will give his or her consent as soon as his or her condition permits.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Adrien TISSOT, Dr | Nantes University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux | Bordeaux | 33604 | France | |||
| CHU de Grenoble |
Not provided
Not provided
Not provided
Not provided
whole blood and serum will be collected and retained in a biorepository
| 3 years |
| T lymphocytes levels over time associated with CLAD | 3 years |
| Grenoble |
| 38700 |
| France |
| Centre Chirurgical Marie Lannelongue | Le Plessis-Robinson | 92350 | France |
| CHU de Lyon | Lyon | 69677 | France |
| AP-HM | Marseille | 13015 | France |
| CHU de Nantes | Nantes | 44093 | France |
| Hôpital Bichat | Paris | 75018 | France |
| CHRU de Strasbourg | Strasbourg | 67091 | France |
| Hôpital Foch | Suresnes | 92151 | France |
| CHU de Toulouse | Toulouse | 31059 | France |